Date of Award

Spring 5-27-2023

Document Type

Doctor of Nursing Practice Final Manuscript

Degree Name

Doctor of Nursing Practice



First Advisor

Pedro Colio, PhD, DNP, FNP-C, ENP-C


Introduction: The purpose of this evidence-based practice project is to improve the utilization of the 2022 ADA pharmacological approach for individuals with Type 2 Diabetic Mellitus (T2DM). The project implementation site was an outpatient clinic in Southern California with a large T2DM Hispanic population. The new ADA guidelines recommend selecting a glucagon-like peptide 1(GLP-1RA) and/or sodium-glucose cotransporter two inhibitors (SGLT-2) when clinically appropriate to reduce the risk of major cardiovascular events in T2DM patients.

Background: According to the American Diabetes Association, ASCVD is the leading cause of morbidity and mortality for adult individuals with T2DM. The use of GLP-1RA and SGLT-2 is supported by both the American Heart Association (AHA) and the 2022 American Diabetes Association (ADA) Standards of Care for managing patients with cardiovascular disease and T2DM.

Methods: This evidence-based project is meant to promote quality improvement utilizing the Iowa Model to translate research findings into clinical practice.

Results: The project's intervention results demonstrated an increase of 5.1% in the utilization of new ADA treatment guidelines by providers.

Evaluation: Managing treatable risk factors that contribute to the development and progression of atherosclerotic disease is essential for reducing the risk of cardiovascular complications. Implementing the ADA recommendations will increase the utilization of new evidence-based cardioprotective therapies.

Keywords: Diabetic Mellitus 2, coronary arterial disease, heart disease, atherosclerotic, hyperlipidemia, hypertension, cerebrovascular accident, myocardial infarct, obese, heart failure, left ventricular hypertrophy, Glucagon-like peptide 1, sodium-glucose co-transporter 2

Included in

Nursing Commons